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Adherence to treatment with artemether–
lumefantrine or amodiaquine–artesunate 
for uncomplicated malaria in children in Sierra 
Leone: a randomized trial
Kristin Banek1* , Emily L. Webb2, Samuel Juana Smith3, Daniel Chandramohan4 and Sarah G. Staedke1
Abstract 
Background: Prompt, effective treatment of confirmed malaria cases with artemisinin-based combination therapy 
(ACT) is a cornerstone of malaria control. Maximizing adherence to ACT medicines is key to ensuring treatment 
effectiveness.
Methods: This open-label, randomized trial evaluated caregiver adherence to co-formulated artemether–lumefan-
trine (AL) and fixed-dose amodiaquine–artesunate (AQAS) in Sierra Leone. Children aged 6–59 months diagnosed with 
malaria were recruited from two public clinics, randomized to receive AL or AQAS, and visited at home the day after 
completing treatment. Analyses were stratified by site, due to differences in participant characteristics and outcomes.
Results: Of the 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis (340 AL, 340 
AQAS). Definite adherence (self-reported adherence plus empty package) was higher for AL than AQAS at both sites 
(Site 1: 79.4% AL vs 63.4% AQAS, odds ratio [OR] 2.16, compared to probable adherence plus probable or definite 
non-adherence, 95% confidence interval [CI] 1.34–3.49; p = 0.001; Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 
1.00–2.33, p = 0.049). However, self-reported adherence (ignoring drug package inspection) was higher for both 
regimens at both sites and there was no strong evidence of variation by treatment (Site 1: 96.6% AL vs 95.9% AQAS, 
OR 1.19, 95% CI 0.39–3.63, p = 0.753; Site 2: 91.5% AL vs 96.4% AQAS, OR 0.40, 95% CI 0.15–1.07, p = 0.067). In Site 2, 
correct treatment (correct dose + timing + duration) was lower for AL than AQAS (75.8% vs 88.1%, OR 0.42, 95% CI 
0.23–0.76, p = 0.004). In both sites, more caregivers in the AQAS arm reported adverse events (Site 1: 3.4% AL vs 15.7% 
AQAS, p < 0.001; Site 2: 15.2% AL vs 24.4% AQAS, p = 0.039).
Conclusions: Self-reported adherence was high for both AL and AQAS, but varied by site. These results suggest that 
each regimen has potential disadvantages that might affect adherence; AL was less likely to be taken correctly at one 
site, but was better tolerated than AQAS at both sites. Measuring adherence to anti-malarials remains challenging, but 
important. Future research should focus on comparative studies of new drug regimens, and improving the methodol-
ogy of measuring adherence.
Trial registration: Clinicaltrials.gov, NCT01967472. Retrospectively registered 18 October 2013, https ://clini caltr ials.gov/
ct2/show/NCT01 96747 2
Keywords: Malaria, Artemisinin-based combination therapy (ACT), Adherence, Compliance, Artemether–
lumefantrine, Amodiaquine, Artesunate, Fixed-dose combination, Co-formulated
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  kristin.banek@lshtm.ac.uk 
1 Department of Clinical Research, London School of Hygiene 
and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Full list of author information is available at the end of the article
Page 2 of 14Banek et al. Malar J  (2018) 17:222 
Background
Universal coverage of diagnostic testing and prompt, 
effective treatment with artemisinin-based combination 
therapy (ACT) are key malaria control strategies [1, 2]. 
However, the effectiveness of malaria case management 
depends on multiple factors, including availability of (and 
access to) treatment with ACT, prescriber compliance to 
guidelines, and importantly, patient (or caregiver) adher-
ence to treatment regimens [3, 4]. Strategies to improve 
adherence, including co-packaging anti-malarial drugs 
into blister packs [5, 6], and co-formulating the partner 
drugs of ACT into a single tablet, have been applied suc-
cessfully [7, 8]. Although co-formulation may improve 
the accuracy of prescription and ease of administration 
of ACT [9], it may not solve all treatment challenges, 
including complex dosing, bitter taste, and side effects 
[10–13]. Furthermore, evidence of the impact of co-for-
mulation on adherence to ACT remains limited [3].
Malaria remains a major health problem in Sierra 
Leone, exacerbated by the Ebola outbreak in 2014, which 
overwhelmed an already fragile health system [14–18]. 
In 2004, co-packaged amodiaquine plus artesunate 
(AQ + AS) was adopted as the first-line recommended 
treatment of malaria, primarily due to affordability and 
availability, with artemether–lumefantrine (AL) as an 
alternative if AQ + AS was not available, or was ineffec-
tive [19]. In 2008, a study of adherence to co-packaged 
AQ + AS in Sierra Leone concluded that only 48.7% 
of participants were probably or definitely adherent to 
treatment [20]. In 2013, with support from The Global 
Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) 
the fixed-dose combination version of amodiaquine–
artesunate (AQAS) replaced the co-packaged AS + AQ 
regimen, with AL remaining as an alternate. However, 
in 2015, following the mass drug administration (MDA) 
campaign during the Ebola outbreak, AL replaced AQAS 
as the treatment of choice for uncomplicated malaria in 
Sierra Leone, with AQAS now as the alternate [21]. The 
impact of these changes in anti-malarial drug policy on 
patient adherence and the overall effectiveness of malaria 
treatment in Sierra Leone remains unclear. To date, no 
studies have evaluated adherence to either AL or AQAS 
in Sierra Leone.
Only three studies have compared the adherence to 
multiple ACT regimens in Africa; however, the pri-
mary outcome of all three studies was treatment effec-
tiveness; adherence was evaluated as a secondary 
outcome [22–24]. Only one of these studies, conducted 
in Benin, compared AL and AQAS [24], finding no sig-
nificant difference in full adherence to AL compared to 
AQAS (83.0% vs 91.0%; p = 0.16). To address this gap 
in evidence, an open-label, randomized trial was con-
ducted in Sierra Leone to compare caregiver adherence 
to co-formulated AL to that of AQAS for treatment of 
uncomplicated malaria in children aged 6–59 months.
Methods
Study sites
The study was conducted at two government-run out-
patient facilities in Freetown, Sierra Leone (Fig. 1). Both 
sites were chosen for their high patient loads, similar 
catchment population and patient numbers as well as 
the size of staff (10–15 health workers per site). Site 1 is 
located in a densely populated area in the eastern part of 
Freetown. The clinic has an estimated catchment popu-
lation of 21,324 people and manages approximately 1000 
patients per month, half of whom are children under 
5  years of age presenting with fever. In 2012, the clinic 
had 400 children under five with confirmed malaria 
every month (extracted from routine health data). Site 
2 is located in the western part of Freetown. This clinic 
has an estimated catchment population of 27,855 people, 
with approximately 800 patient visits per month. In 2012, 
60% of patients were children under 5 years of age pre-
senting with fever, including an average of 240 confirmed 
malaria cases each month (routine health data).
Study procedures
Children were enrolled in the study, if they met the fol-
lowing inclusion criteria: (1) age 6–59 months; (2) com-
plaint of fever or history of fever; (3) living within 5 km 
of health facility; (4) no evidence of severe malaria or 
danger signs (i.e. inability to eat/drink, extreme leth-
argy, inability to sit/stand, difficulty breathing, jaundice, 
severe dehydration, convulsion or persistent vomiting) 
[2, 21, 25]; (5) not referred to another health facility; 
(6) not previously enrolled in the study; and (7) written 
informed consent to participate in the study provided by 
their parent or guardian. During the consenting process, 
caregivers were informed about the purpose of the study, 
but were not told that they would be visited at home or 
that their adherence to treatment guidelines would be 
assessed.
Following enrolment, study participants were sub-
ject to the standard of care provided at the health cen-
tres. All participants first underwent testing for malaria 
using rapid diagnostic tests (RDTs) at the health centre 
laboratory, and then saw a consulting health worker for a 
clinical evaluation. Study staff recorded RDT results onto 
case record forms, and observed patient-provider con-
sultations for all participants. Children who had a posi-
tive RDT and were diagnosed with malaria by the health 
worker were randomly assigned to receive treatment with 
either AL or AQAS and were scheduled for a home visit 
on Day 4. If the RDT was negative for malaria, the child 
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Fig. 1 Map of the study area. Blue dots—study sites
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was excluded from the study and was provided standard 
care by the health worker.
Study medication
Co-formulated AL (Coartem  Dispersible®: Novartis) 
was procured by the research team and provided to both 
sites for the purpose of this study. Fixed-dose AQAS 
 (Winthrop®: Sanofi-Aventis) was available at both study 
sites through the standard government supply chain 
system. All study medications were produced by manu-
facturers pre-qualified by the World Health Organiza-
tion (WHO) and approved by the Pharmacy Board of 
Sierra Leone, and were prescribed according to standard 
national and WHO treatment guidelines [25, 26].
Participants randomized to treatment with AL received 
20/120  mg tablets dosed appropriately twice a day for 
3  days. Health workers prescribed treatment based on 
weight when possible; if weighing scales were not avail-
able, treatment was prescribed by age. Children aged 
6–11 months (or weighing 5–15 kg) received 1 tablet per 
dose (infant dose), and those aged 12–59 months of age 
(or weighing > 15 to 20  kg) received 2 tablets per dose 
(child dose). Participants randomized to treatment with 
AQAS received one tablet dosed appropriately for age (or 
weight) once daily for 3 days. Children aged 6–11 months 
(or weighing 4.5–8 kg) received the infant dose (67.5 mg 
AQ/25 mg AS tablets) and children aged 12–59 months 
(or weighing 9–17  kg) received the child dose (136  mg 
AQ/50  mg AS tablets). Caregivers were responsible for 
administering the treatments to their child as instructed 
by the health worker.
Randomization and blinding
A computer-generated randomization list (in blocks of 
10) was created for each site by a member of the team 
who was not directly involved in patient recruitment, 
consultation or follow-up. Prior to study initiation, indi-
vidual treatment allocation slips were prepared from the 
randomization list. These were sealed into sequentially-
numbered, opaque envelopes containing the treatment 
group assignments. The consulting health worker opened 
the envelopes and assigned the treatment number and 
corresponding treatment at the time of prescription. 
Health facility nurses were responsible for dispensing 
the study medications according to the assigned study 
number. Study medications were not identical in appear-
ance or taste nor were the tablets per dose the same. The 
participants, health workers, and study team were not 
blinded to the treatment assignments.
Follow‑up
Study participants were visited at home 4 days after their 
clinic visit; the day after the last treatment dose should 
have been taken. The purpose of the follow-up visit 
was explained to the caregivers, and additional written 
informed consent for the interview was obtained; par-
ticipation was voluntary [27]. If the participating child 
required further medical attention at the time of the 
home visit, s/he was immediately referred to the nearest 
health centre, and the adherence assessment was con-
ducted the following day, if the participant’s condition 
had improved. No interviews were carried out more than 
5 days after the initial clinic visit.
A semi-structured questionnaire was administered to 
caregivers to assess adherence to treatment, the charac-
teristics of the child and caregiver, knowledge of malaria, 
household characteristics, and wealth indicators. Car-
egivers were asked to describe the treatment, including 
how the medication was administered and any adverse 
events, and to show the original medication packaging. If 
the packaging was available, any remaining tablets were 
tallied and recorded onto the questionnaire. If treatment 
had not been completed at the time of the follow-up visit, 
the caregiver was encouraged to complete the full treat-
ment course or, if that was not possible, to return to the 
health facility.
Statistical methods
Sample size
In 2010, the prevalence of adherence to co-packaged 
AQ + AS in Sierra Leone was estimated to be 50% [20]. 
Based on studies in other countries, it was estimated that 
fixed-dose AQAS would yield a higher level of adherence 
(conservatively estimated to be 75%) [24, 28]. At the time 
of the study, there was no data on adherence levels to AL 
in Sierra Leone, however, based on the literature it was 
hypothesized that adherence to AL would be greater than 
co-packaged AQ + AS, but less than fixed-dose AQAS 
[3, 29]. In order to determine a 15% or greater absolute 
difference between the different treatment groups (two-
sided test, 5% significance level, 80% power, 20% contin-
gency (i.e. loss to follow-up, missing data etc.), a total of 
198 patients were required for each treatment arm. As 
differences in context, health system and/or socioeco-
nomic factors may influence adherence, the study was 
powered to detect differences in adherence to the two 
treatments, separately at each site. Thus, the sample size 
for each site was 400.
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Outcome measures
Using previous ACT adherence studies as a guide, the 
primary outcome of caregiver adherence was based on 
self-reports of completion of treatment and, when pos-
sible, verified by package inspection [3, 29, 30]. Adher-
ence was classified into four categories: (1) “definitely 
adherent”: caregiver reported completion of treatment 
and verified by an empty package; (2) “probably adher-
ent”: reported completion of treatment but no package 
available for verification; (3) “probably non-adherent”: 
reported non-completion of treatment, but no package 
available for verification; and (4) “definitely non-adher-
ent”: reported non-completion of the treatment verified 
by a package with remaining tablets.
As the main outcome variable was derived from two 
different measurements, the variable was recoded to pro-
duce two binary variables representing each component. 
These included: (1) “self-reported adherence”, which does 
not consider package availability (thus, self-reported 
adherence = definitely adherent + probably adherent; 
non-adherence = probably non-adherent + definitely 
non-adherent); and (2) “package-based adherence”, 
which does not consider self-reported adherence (thus 
package-based adherence = definitely adherent; non-
adherence = probably adherent + probably non-adher-
ent + definitely non-adherent).
Secondary outcomes were adherence to the pre-
scribed number of doses, time-schedule and duration of 
treatment. The correct number of doses was defined as 
receiving the prescribed number of tablets, as indicated. 
Correct timing was defined as receiving the ACT at the 
prescribed intervals (twice daily for AL and once daily 
for AQAS). Correct duration was defined as receiving 
the ACT for the recommended number of days (3  days 
for both regimens). Correct treatment was defined as 
the composite of the three above indicators: correct 
dose + correct timing + correct duration, in which all 
three factors were met.
Data management and analysis
Data were recorded on paper forms and entered into a 
database created in Epi Info™ 7.1.2.0 (Centers for Dis-
ease Control and Prevention (CDC), Atlanta, GA USA). 
Data were double entered into tablets using the Epi Info 
Companion for Android mobile application. Statistical 
analysis was performed using Stata 12 (StataCorp, Col-
lege Station, TX USA).
Although intention-to-treat analysis is the preferred 
analytic approach for randomized controlled trials, a per-
protocol analysis was favoured for this trial as the pri-
mary outcome was adherence. The main objective of this 
study was to assess the behaviours of caregivers related to 
the specific ACT received at the health facility. Therefore, 
the primary analyses were carried out using the per-pro-
tocol population, in which only children who received 
ACT as per the randomization schedule and had out-
come data were included. Children who did not receive 
the correct ACT regimen based on the randomization 
list were excluded from this analysis. We also conducted 
and present the intention-to-treat analysis for compari-
son with the per-protocol findings, to assess whether 
results from the two analytic approaches were similar. 
Participant’s characteristics and adverse events were tab-
ulated by study site and randomization group in the per-
protocol population. The wealth index was created using 
principle component analysis (PCA) [31].
Chi squared or Fisher’s exact tests were used to com-
pare categorical data, and continuous data were tested 
using Student’s or Welch’s t-tests. Measures of effect 
(odds ratios-OR) were calculated using logistic regres-
sion for binary outcomes and ordinal logistic regression 
for multinomial outcomes along with the 95% confidence 
intervals and associated p-values. For the ordinal logistic 
regression model, the proportional odds assumption was 
tested with a likelihood ratio test.
Ethical considerations
The study protocol was approved by the London School 
of Hygiene and Tropical Medicine (LSHTM) Research 
Ethics Committee and the Sierra Leone Ethics and Sci-
entific Review Committee. The trial was registered at 
ClinicalTrials.gov (NCT01967472; https ://clini caltr ials.
gov/ct2/show/NCT01 96747 2). All participants provided 
written informed consent at the time of recruitment and 
again prior to administration of the follow-up survey in 
their homes.
Results
Enrolment
The study was conducted from September 2013 to Janu-
ary 2014. Of the 1979 children screened (Fig. 2), 834 were 
excluded at screening, and 361 were excluded after test-
ing negative for malaria. A total of 784 children were 
randomized to malaria treatment (390 at Site 1; 394 at 
Site 2); of these, 77 (9.7%) were excluded after randomi-
zation (lost to follow-up = 55, missing data = 18, refused 
1, serious adverse event = 3; Fig. 2). The total number of 
children analysed in the intention-to-treat population 
was 707 (353 at Site 1 and 354 at Site 2). Treatment was 
misallocated in an additional 27 cases (6 at Site 1; 21 at 
Site 2); these children were excluded from the per-pro-
tocol analysis. Thus, 680 (85.6%) randomized children 
were included in the final per-protocol analysis (347 at 
Site 1; 333 at Site 2). Analyses were carried out for both 
the intention-to-treat and per-protocol populations, 
but all tables present the results from the per-protocol 
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Fig. 2 Study profile. RDT, rapid diagnostic test; AQAS, fixed-dose combination amodiaquine–artesunate; AL, artemether–lumefantrine; SAE, serious 
adverse event
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population. The intention-to-treat analysis is also pre-
sented for both the primary and secondary outcomes, 
but there is little if any difference between the findings.
Characteristics of participants, caregivers, and households
The characteristics of participants and their caregivers 
and households were significantly different at the two 
study sites, therefore, all results are presented stratified 
by site (Table  1). Participants at Site 1 were younger 
than those at Site 2 (mean age 15 months vs 24 months, 
respectively, p < 0.001). No child at either site had been 
treated previously with AL, while some had received 
fixed-dose AQAS (41.3% at Site 1; 28.6% at Site 2; 
p = 0.025). Few caregivers reported that their child dis-
liked AL, but complaints about AQAS were more com-
mon (19.8% at Site 1; 15.5% at Site 2; p = 0.550). At both 
sites, only caregivers in the AQAS arm reported that 
their child complained of bitter taste.
Caregivers were also younger at Site 1 (median age of 
25  years at Site 1 vs 27  years at Site 2, p < 0.001); most 
Table 1 Characteristics of participants, caregivers and  householdsa
a Demographic data were collected during follow-up visits; therefore, this information is only available from participants that were located and consented for the 
follow-up interviews (the per-protocol population)
b Scale availability was problematic at both sites on select days, so weight data is not available for some participants. Denominators for weight: Site 1: AL = 165; 
AQAS-164; Site 2: AL = 151; AQAS = 152
c Religion: information on religion is missing from one participant in the AL group at Site 2 (n = 164)
d Wealth index denominators: Site 1 AL = 169 and AQAS = 171; Site 2 AL = 164 and AQAS = 167
Site 1 Site 2
AL (N = 175) AQAS (N = 172) AL (N = 165) AQAS (N = 168)
Participant characteristics
Weightb, kg [median (IQR)] 10 (8, 11) 10 (8, 11.4) 10 (8, 13) 10 (9, 13)
Age, months [median (IQR)] 15 (10, 24) 16 (11, 32.5) 24 (14, 37) 24 (14, 42.5)
Age categorized
 6 to 24 months 132 (75.4%) 116 (67.4%) 88 (53.3%) 85 (50.6%)
 25 to 59 months 43 (24.6%) 56 (32.6%) 77 (45.7%) 83 (49.4%)
Gender (% female) 82 (46.9%) 72 (41.9%) 79 (47.9%) 76 (45.2%)
Previously taken the antimalarial treatment
 No 173 (98.9%) 97 (56.4%) 165 (100%) 118 (70.2%)
 Yes 0 (0.0%) 71 (41.3%) 0 (0.0%) 48 (28.6%)
 Unknown 2 (1.1%) 4 (2.3%) 0 (0.0%) 2 (1.2%)
Disliked the antimalarial treatment
 No 156 (89.1%) 128 (74.4%) 153 (92.7%) 130 (77.4%)
 Yes 2 (1.1%) 34 (19.8%) 7 (4.2%) 26 (15.5%)
 Unknown 17 (9.7%) 10 (5.8%) 5 (3.0%) 12 (7.1%)
Complained of bitter taste 0 (0.0%) 31 (18.0%) 0 (0.0%) 18 (10.7%)
Caregiver characteristics
Age, years [median (IQR)] 25 (21, 30) 25 (21, 29) 27 (22, 34) 27 (23, 34)
Gender (% female) 169 (96.6%) 166 (96.5%) 156 (94.6%) 162 (96.4%)
Fluent in Krio 123 (70.3%) 124 (72.1%) 116 (70.3%) 118 (70.2%)
Any education 107 (61.1%) 86 (50.0%) 109 (66.1%) 116 (69.1%)
Told to finish treatment by health worker 101 (57.7%) 101 (58.7%) 85 (51.5%) 73 (43.5%)
Knowledge about ACTs 31 (17.7%) 35 (20.4%) 54 (32.7%) 51 (30.4%)
Household characteristics
Religionc
 Christian 27 (15.4%) 22 (12.8%) 77 (46.7%) 91(54.2%)
 Muslim 148 (84.6%) 150 (87.2%) 87 (52.7%) 77 (45.8%)
Household wealth  indexd
 1 (poorest) 40 (23.7%) 47 (27.5%) 77 (47.0%) 72 (43.1%)
 2 59 (34.9%) 61 (35.7%) 42 (25.6%) 47 (28.1%)
 3 (least poor) 70 (41.4%) 63 (36.8%) 45 (27.4%) 48 (28.7%)
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caregivers (> 70%) spoke Krio (the local language) at 
both sites. In Site 1, caregivers in the AL arm were more 
educated than those in the AQAS arm (61.1% vs 50.0%, 
respectively, p = 0.040). At both sites, approximately half 
of caregivers reported that health workers instructed 
them to finish the anti-malarial treatment. Caregiver 
knowledge about ACT was low at both sites, more so in 
Site 1.
The Muslim religion was practised by substantially 
more households at Site 1 than at Site 2 (85.9% vs 49.2%, 
respectively, p < 0.001). Households at Site 2 were signifi-
cantly poorer than at Site 1, with 149 (44.7%) households 
assigned to the poorest category at Site 2 vs 87 (25.1%) 
in Site 1 (p < 0.001). Otherwise, there were no additional 
differences in characteristics of participants, caregivers 
or households, between trial arms, at either site.
Adherence
At both sites, the odds of definite adherence (defined 
as self-reported adherence in the presence of an empty 
drug package) were higher for AL than AQAS (Table 2). 
Self-reported adherence (ignoring the results of the drug 
package inspection) was > 90% for both regimens, but 
varied between the sites. At Site 1, self-reported adher-
ence to AL was slightly higher than to AQAS, but at Site 
2, self-reported adherence to AQAS was greater than to 
AL. However, adherence determined by inspecting drug 
packaging alone was higher for AL than AQAS at both 
sites; adherence (defined by empty packaging) to both 
Table 2 Primary adherence outcomes
*Odds Ratios were calculated using ordinal logistic regression for the primary adherence outcome and logistic regression for the binary outcomes with ORs calculated 
using AQAS as the reference group
a Definitely adherent = self-reported adherence + empty package; probably adherent = self-reported adherence (no package); probably non-adherent = self-
reported non-adherence (no package); definitely non-adherent = self-reported non-adherence + package with tablets remaining
b Adherent = definitely adherent + probably adherent
c Adherent = only definitely adherent
Site 1 Site 2
AL AQAS OR (95%CI)
p‑value*
AL AQAS OR (95%CI)
p‑value*
Per‑Protocol N = 175 N = 172 N = 165 N = 168
Primary adherence  outcomea
 Definitely non-adherent 2 (1.1%) 3 (1.7%) 2.16 (1.34− 3.49)
0.001
10 (6.1%) 5 (3.0%) 1.53 (1.00− 2.33)
0.049 Probably non-adherent 4 (2.3%) 4 (2.3%) 4 (2.4%) 1 (0.6%)
 Probably adherent 30 (17.1%) 56 (32.6%) 65 (39.4%) 99 (58.9%)
 Definitely adherent 139 (79.4%) 109 (63.4%) 86 (52.1%) 63 (37.5%)
Self-reported  adherenceb
 Non-adherent 6 (3.4%) 7 (4.1%) 1.19 (0.39− 3.63)
0.753
14 (8.5%) 6 (3.6%) 0.40 (0.15− 1.07)
0.067 Adherent 169 (96.6%) 165 (95.9%) 151 (91.5%) 162 (96.4%)
Adherence based on  packagingc
 Non-adherent 36 (20.6%) 63 (36.6%) 2.23 (1.38− 3.61)
0.001
79 (47.9%) 105 (62.5%) 1.81 (1.17− 2.81)
0.008 Adherent 139 (79.4%) 109 (63.4%) 86 (52.1%) 63 (37.5%)
Intention‑to‑treat N = 179 N = 174 N = 178 N = 176
Primary adherence  outcomed
 Definitely non-adherent 2 (1.1%) 3 (1.7%) 2.15 (1.35− 3.44)
0.001
11 (6.2%) 6 (3.4%) 1.40 (0.93− 2.10)
0.109 Probably non-adherent 4 (2.3%) 4 (2.3%) 4 (2.3%) 1 (0.6%)
 Probably adherent 32 (17.9%) 58 (33.3%) 73 (41.0%) 101 (57.4%)
 Definitely adherent 141 (78.8%) 109 (62.6%) 90 (50.6%) 68 (38.6%)
Self-reported  adherenceb
 Non-adherent 6 (3.4%) 7 (4.0%) 1.21 (0.40− 3.67)
0.738
15 (8.4%) 7 (4.0%) 0.45 (0.18− 1.13)
0.090 Adherent 173 (96.7%) 167 (96.0%) 163 (91.6%) 169 (96.0%)
Adherence based on  packagingc
 Non-adherent 38 (21.2%) 65 (37.4%) 2.21 (1.38− 3.55)
0.001
88 (49.4%) 108 (61.4%) 1.62 (1.06− 2.48)
0.024 Adherent 141 (78.8%) 109 (62.6%) 90 (50.6%) 68 (38.6%)
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regimens was higher at Site 1 than Site 2. This variability 
in findings reflects differences in the retention of the drug 
package by caregivers, which was significantly higher at 
Site 1 than at Site 2 (263 [75.8%] vs 185 [52.6%], respec-
tively, p < 0.001; Additional file  1). In addition, at both 
sites, significantly more caregivers saved AL packages 
than AQAS packages (Site 1: AL 147 [84.0%] vs AQAS 
116 [67.4%], p < 0.001; Site 2: AL 103 [62.4%] vs AQAS 72 
[42.9%], p < 0.001).
Quality of treatment
Overall, the quality of treatment was high (Table  3). 
At both sites, nearly all participants received the total 
required tablets for both regimens. At Site 1, the mean 
proportion of number of tablets taken was higher, but 
not significantly, for AL (99.8%), while the opposite was 
found at Site 2, where the mean proportion of tablets 
received was marginally higher for AQAS (99.2%). Subtle 
differences in treatment patterns were found at both sites. 
At Site 1, significantly fewer AQAS participants received 
the appropriate number of tablets for their weight (cor-
rect dose), but fewer AL participants were treated the 
correct number of times per day (correct timing), and for 
the correct number of days (correct duration), although 
these findings were not statistically significant. At Site 2, 
AL participants were significantly less likely to be treated 
with the appropriate number of tables and for the correct 
number of times per day (correct dose and correct tim-
ing), and were less likely to receive the correct treatment 
overall (correct dose + timing + duration), than AQAS 
participants.
Adverse events
A total of 106 caregivers reported that their child experi-
enced an adverse event to treatment. Significantly more 
adverse events were reported at Site 2 than at Site 1 (66 
[19.8%] vs 33 [9.5%], respectively, p < 0.001). At both 
sites, significantly more caregivers in the AQAS arm 
reported adverse events (Table 4), with vomiting, weak-
ness-fatigue, and dizziness most commonly reported. 
At Site 1, significantly more caregivers in the AQAS 
arm reported that their child vomited, or was weak or 
dizzy. Similar results were seen at Site 2, but only weak-
ness was reported by significantly more caregivers in the 
AQAS arm. Three serious adverse events, including two 
hospitalizations for severe malaria and one death, were 
reported during the study period, but none were felt to 
be related to the study medications. The cause of death 
was unknown for the child that died. However, the child 
was noted by the study staff to have danger signs sugges-
tive of severe disease, and was referred, but unfortunately 
the caregiver did not seek further care.
Discussion
With progress on malaria control slowing and resist-
ance to artemisinin resistance emerging, it is vital that 
every effort is made to protect the efficacy of ACT [32]. 
Patient adherence to prescribed anti-malarial regimens is 
a key step in the pathway to treatment effectiveness [4]. 
Yet, evidence on the impact of co-formulation of drug 
regimens, and comparative data on adherence to avail-
able ACT, is limited [3]. In this randomized trial, self-
reported adherence was high for both co-formulated AL 
and AQAS, but varied by study site. At both sites, definite 
adherence was significantly higher for AL than AQAS. 
However, this outcome was influenced by the likelihood 
of retention of the drug package by caregivers, which was 
significantly higher for AL. Overall, the quality of treat-
ment was high; however, disadvantages to both regimens 
were identified that could negatively impact adherence. 
AL was less likely to be administered correctly at one 
site, which is not surprising given the greater complex-
ity of the dosing regimen. AQAS was less well-tolerated 
at both sites, and was associated with bitter taste and 
significantly more adverse events. To better understand 
adherence to ACT, and how adherence might impact on 
treatment effectiveness, additional studies are warranted, 
particularly comparative studies including ACT and new 
drug regimens as these become available. Standardiz-
ing methodologies for evaluating adherence would also 
improve the evidence base on ACT adherence.
Currently, the available evidence on ACT adherence is 
limited by variation in study designs and outcomes, dif-
ferences in drug regimens, and lack of comparative stud-
ies [3]. In prior randomized trials, adherence to AL has 
ranged from 64 to 99% [33–38]. Similarly, adherence to 
co-packaged AQ + AS and AQAS has varied widely in 
prior studies. In Sierra Leone, adherence to co-packaged 
AQ + AS was only 48% [20], while in Zanzibar and Ghana 
adherence to AQ + AS was much higher (77 and 93%, 
respectively) [39, 40]. Two recent studies from The Dem-
ocratic Republic of Congo reported adherence to fixed-
dose AQAS to be 75 and 62% [41, 42], and in a study in 
Madagascar, adherence to AQAS was even higher (90%) 
[28].
The one other study that directly compared adher-
ence to AL and AQAS in Benin found that ‘full adher-
ence’ to the two regimens was not significantly different 
[24]. However, this study primarily evaluated treatment 
effectiveness, with adherence as a secondary outcome; 
little information was provided about how adherence 
was defined and measured. Apparently, adherence was 
assessed during a home visit on Day 3 of treatment and 
drug packages were collected when available, but it is not 
clear how ‘full adherence’ was defined, limiting the abil-
ity to compare their results to findings from this study. 
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The results reported here build on the available evidence, 
suggesting that self-reported adherence to both AL and 
AQAS are high, and highlighting methodological chal-
lenges that should be addressed in future studies.
This study also identified specific characteristics which 
may impact adherence to AL and AQAS. AL was less 
likely to be taken correctly at one site, but was better tol-
erated than AQAS at both sites. The complexity of the AL 
dosing regimen, including the number of tablets, twice 
daily dosing, the requirement to give the second dose 8 h 
after the first, and to administer with fatty food [43], has 
been shown to negatively impact treatment adherence 
[44, 45]. In contrast, while AQAS has been optimized 
to be dosed only once daily [46–48], its bitter taste and 
greater likelihood of adverse events make it more difficult 
to administer to children [49, 50], and may reduce adher-
ence as found in this study. Pharmaceutical companies 
have focused on producing child-friendly ACT formula-
tions, including smaller tablets, dispersible tablets, and 
improved weight-for-age dosing recommendations [10, 
12, 51, 52]. As new anti-malarial drugs are developed and 
evaluated for effectiveness, it will be important to assess 
child-friendly regimens that are palatable and easy to 
administer, in order maximize treatment adherence and 
outcomes in those affected most by malaria [53].
In this study, adherence to AL and AQAS varied 
depending on the outcome definition applied. Although 
definitions of adherence outcomes, based on self-report 
of treatment completion plus package inspection, which 
have been used in previous anti-malarial studies were 
adopted [3, 29, 30], limitations to these definitions were 
found. Both indicators used to define adherence are sub-
ject to bias. Self-reported adherence is open to social 
desirability bias, with caregivers more likely to report 
what they perceive to be ‘correct’ answers, potentially 
leading to over-estimation of adherence. Package inspec-
tion and pill counts, while more ‘objective’ measures [54, 
55], are dependent on the availability of packaging. In the 
Benin study, more AQAS packages were found (84.4% of 
AL vs 93.7% of AQAS packages) [24], in contrast to this 
study, in which more AL packages were retained. Fac-
tors that influence desirability of retaining packaging 
could also impact on adherence. Prior research suggests 
that novel drug packages, that aim to educate or market 
a drug regimen, may be more attractive or appealing, 
and thus may be more likely to be retained [56, 57], thus 
impacting on measures of adherence that incorporate 
data from package examinations, or may impact adher-
ence directly [58].
A variety of approaches have been used to incorporate 
package inspection in the classification of adherence out-
come [36, 59, 60]. Under trial conditions, blister packages 
have been retained and inspected with results success-
fully incorporated into the outcome measurement [61]. 
In other studies, package inspection has been included 
in the methods, but either excluded from the analysis 
[62], or not utilized altogether. For example, although 
the packaging was part of the outcome definition, the 
proportion of packaging available was not reported in 
a number of studies [35, 41, 42]. In others, the package 
information although collected, was not utilized and only 
self-reported (probable) adherence rates were reported 
[44, 63, 64]. In Ghana, an intervention study used pack-
age inspection as a secondary outcome to validate self-
reported adherence, but found that only 60% of patients 
were able to produce their package, suggesting that this 
Table 4 Reported adverse events (side effects)
* Fisher’s exact test
a Reported one or more of the following: diarrhoea, anorexia, nausea or abdominal pain
b  Other AE’s reported: Site 1— AL: 1 pruritic; AQAS: 1 headache & 1 not specified. Site 2—AL: 2 change in urine colour, 1 cold/flu, & 1 sweating; AQAS: 1 change in 
urine colour, 1 fever, 1 mouth sores & 1 unspecified
Site 1 Site 2
AL (N = 175) AQAS (N = 172) p‑value* AL (N = 165) AQAS (N = 168) p‑value*
Any adverse event
 Caregiver reported 6 (3.4%) 27 (15.7%) < 0.001 25 (15.2%) 41 (24.4%) 0.039
Specific adverse events
 Vomiting 4 (2.3%) 16 (9.3%) 0.005 13 (7.9%) 18 (10.7%) 0.452
 Weakness-Fatigue 0 (0.0%) 12 (7.0%) < 0.001 9 (5.5%) 29 (17.3%) 0.001
 Dizziness 0 (0.0%) 10 (5.8%) 0.001 7 (4.2%) 4 (2.4%) 0.376
 Diarrhoea 1 (0.6%) 3 (1.7%) 0.369 2 (1.2%) 2 (1.2%) 1.000
 Other gastrointestinal 
 complaintsa
1 (0.6%) 5 (2.9%) 0.119 2 (1.2%) 4 (2.4%) 0.685
 Other AE  reportedb 1 (0.6%) 2 (1.2%) 0.621 4 (2.4%) 4 (2.4%) 1.000
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may not be the most accurate measurement of ACT 
adherence [36]. Likewise, in Ethiopia, difficulties with 
package retention over many days were reported, sug-
gesting that presence of packaging may not be indicative 
of true adherence [50].
Although package inspections and pill counts serve as 
a gold standard for measuring adherence to treatment of 
other diseases [54, 65] the heterogeneity of this outcome 
measure in malaria studies limits comparison of adher-
ence to regimens across studies. Instead, examining the 
quality of treatment, including whether the correct num-
ber of tablets were given at the correct frequency for 
the correct number of days, may provide a more accu-
rate picture of treatment adherence [35, 37, 59, 63, 66]. 
Recently studies measuring anti-malarial adherence have 
presented per-dose adherence measurements [36, 59, 
61], this approach is useful as it can illustrate at which 
point patients stop taking their medications. However, 
this approach like those mentioned earlier relies on self-
report, with or without package validation. Standardizing 
methodologies for evaluating adherence is necessary to 
improve the evidence base on ACT adherence.
This study had several limitations, in addition to the chal-
lenges with the adherence outcome classification. First, the 
characteristics of the participants, caregivers, and house-
holds enrolled in the two sites varied substantially, which 
was unexpected. Specifically, variations in the age of par-
ticipating children, level of caregiver education, household 
religion and socioeconomic position were found, all of 
which may influence treatment adherence [3, 29, 67, 68]. 
To address these differences, the analysis was stratified 
by study site. Stratification did not impact on the power 
to detect differences in adherence outcomes, as the sam-
ple size calculations were done independently for the two 
sites, in case differences in the sites were found. Second, an 
unexpectedly high number of children were excluded after 
testing with RDT and after randomization, particularly at 
Site 2. In addition, several children received the incorrect 
treatment, again more commonly at Site 2. These exclu-
sions and the imbalance between sites were likely due to 
characteristics of the health centres, and random error. No 
systematic biases were suspected. Furthermore, to exam-
ine the validity of the findings, a sensitivity analysis was 
conducted comparing outcome measures in the ITT and 
PP populations, which found that outcome measurements 
were almost identical for both analytical approaches, sug-
gesting that the exclusions after randomization did not 
impact the outcomes presented here. Third, the design 
of this study may have led to an overestimation of adher-
ence. Effectiveness trials and cross-sectional studies have 
been shown to report higher adherence levels than pro-
spective observational studies; however, even results from 
such studies vary [3, 30]. Moreover, although this study did 
occur under ‘normal conditions’, the fact that providers and 
caregivers were observed, may have altered their behav-
iour as a result of participating in the study (participation 
bias), and influenced adherence outcomes [29, 69]. Finally, 
the limitations of only looking at statistical significance 
should be noted, as statistically significant differences do 
not always equate to clinical importance. This study was 
powered to detect a 15% difference in rates of adherence 
between AL and AQAS, with the thinking that if the abso-
lute difference in adherence between the two regimens 
was 15% or more that this would a big enough difference 
from a clinical or public health perspective to favour one 
treatment over the other. From a public health perspec-
tive, the findings of this study did not find a difference large 
enough to favour one regimen over another; however, the 
secondary outcome (correct treatment and its associated 
components) does hightlight operational areas where ACT 
administration could be improved.
Conclusion
Maximizing adherence to anti-malarial drug regimens is 
essential for ensuring treatment effectiveness; however 
measuring adherence remains challenging. The results 
from this study suggest that although self-reported adher-
ence to both AL and AQAS was high, the difference 
between the two regimens was not significant. However, 
potential disadvantages were identified for each regimen 
that might impact optimal treatment adherence. With 
the emergence of resistance to artemisinins in Southeast 
Asia fuelling the development of new drug formulations, 
information on adherence to different ACT regimens will 
become increasingly important to help guide drug delivery, 
improve treatment effectiveness, and inform drug policy. 
However, the methodology of measuring adherence in 
anti-malarial studies requires further advancement. This 
study highlights the limitations of package inspection, and 
suggests that an outcome measure based on correct treat-
ment could have greater utility. Standardizing method-
ologies for evaluating adherence across diverse contexts 
would improve the evidence base on ACT adherence and 
effectiveness.
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